SCHEMBL899149

SCHEMBL899149

Cc1cc([N+](=O)[O-])cc(Cl)n1

nearest known ligand 0.48

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.48
ALDH1A1 P00352 6/20 0.47
HTT P42858 2/20 0.45
MAPT P10636 2/20 0.41
CYP19A1 P11511 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.40
HSD17B10 Q99714 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
MEN1 O00255 1/20 0.39
LMNA P02545 1/20 0.39
KMT2A Q03164 1/20 0.39
PIK3C3 Q8NEB9 1/20 0.39
ABCB1 P08183 1/20 0.39
ABCC1 P33527 1/20 0.39
ABCG2 Q9UNQ0 1/20 0.39
GPR35 Q9HC97 2/20 0.39
S1PR4 O95977 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2437759 0.85 TSHR (0.58) TSHRALDH1A1HTTMAPTCYP19A1
SCHEMBL805900 0.85 ALDH1A1 (0.56) TSHRALDH1A1HTTCYP19A1HSD17B10
Ammonia Solution, Strong SCHEMBL28208001 0.83 TSHR (0.56) TSHRALDH1A1HTTMAPTCYP19A1
SCHEMBL5864975 0.76 TSHR (0.48) TSHRALDH1A1HTTMAPTCYP19A1
SCHEMBL31481313 0.76 MAPT (0.51) TSHRALDH1A1HTTMAPTCYP19A1
SCHEMBL5652028 0.76 TSHR (0.48) TSHRALDH1A1HTTMAPTCYP19A1
SCHEMBL29664408 0.76 TSHR (0.48) TSHRALDH1A1HTTMAPTCYP19A1
SCHEMBL10962494 0.73 TSHR (0.45) TSHRALDH1A1HTTMAPTCYP19A1
SCHEMBL11843690 0.73 TSHR (0.45) TSHRALDH1A1HTTMAPTCYP19A1
SCHEMBL1797796 0.72 ALDH1A1 (0.49) TSHRALDH1A1HTTMAPTL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12391663-B2 Isoindolinone compounds MONTE ROSA THERAPEUTICS AG (CH) 2025-08-19 US disclosed
CN-114945571-B Cyclic compounds and methods of use thereof 薛定谔公司 2025-02-25 CN disclosed
US-20240261274-A1 TREATMENT OF MYC-DRIVEN CANCERS WITH GSPT1 DEGRADERS MONTE ROSA THERAPEUTICS AG (CH) 2024-08-08 US disclosed
US-20240216355-A1 PHARMACEUTICAL COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF A DISEASE OR DISORDER CAUSED BY OR ASSOCIATED WITH ONE OR MORE PREMATURE TERMINATION CODONS MONTE ROSA THERAPEUTICS AG (CH) 2024-07-04 US disclosed
US-20240083869-A1 ISOINDOLINONE COMPOUNDS MONTE ROSA THERAPEUTICS AG (CH) 2024-03-14 US disclosed
US-11926632-B2 Methods and compounds for restoring mutant p53 function PMV PHARMACEUTICALS, INC. (US) 2024-03-12 US disclosed
US-11912682-B2 Isoindolinone compounds MONTE ROSA THERAPEUTICS, INC. (US) 2024-02-27 US disclosed
EP-4323349-A1 ISOINDOLINONE AMIDE COMPOUNDS USEFUL TO TREAT DISEASES ASSOCIATED WITH GSPT1 Monte Rosa Therapeutics AG (CH) 2024-02-21 EP disclosed
US-20240051937-A1 ISOINDOLINONE AMIDE COMPOUNDS USEFUL TO TREAT DISEASES ASSOCIATED WITH GSPT1 MONTE ROSA THERAPEUTICS AG (CH) 2024-02-15 US disclosed
EP-4313047-A1 PHARMACEUTICAL COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF A DISEASE OR DISORDER CAUSED BY OR ASSOCIATED WITH ONE OR MORE PREMATURE TERMINATION CODONS Monte Rosa Therapeutics, Inc. (US) 2024-02-07 EP disclosed
US-7884112-B2 Glycogen phosphorylase inhibitor; antidiabetic agents; hypoglycemic agents; hypercholesterolemia; hypotensive agents; antilipemic agents; hypotensive agents; antiischemic agents BRADLEY STUART EDWARD 2011-02-08 US disclosed
EP-1725555-B1 PYRROLOPYRIDINE-2-CARBOXYLIC ACID HYDRAZIDES AS INHIBITORS OF GLYCOGEN PHOSPHORYLASE PROSIDION LTD (GB) 2010-10-06 EP disclosed
US-20080269277-A1 Pyrrolopyridine-2-Carboxylic Acid Hydrazides BRADLEY STUART EDWARD 2008-10-30 US disclosed
EP-1725555-A1 PYRROLOPYRIDINE-2-CARBOXYLIC ACID HYDRAZIDES AS INHIBITORS OF GLYCOGEN PHOSPHORYLASE Prosidion Ltd. (GB) 2006-11-29 EP disclosed
WO-2005085245-A9 PYRROLOPYRIDINE-2-CARBOXYLIC ACID HYDRAZIDES 2006-01-05 WO disclosed
WO-2005085245-A1 PYRROLOPYRIDINE-2-CARBOXYLIC ACID HYDRAZIDES PROSIDION LIMITED (GB) 2005-09-15 WO disclosed
US-4786317-A 4-phenoxy-pyridines having herbicidal activity CELAMERCK GMBH & CO. KG (DE) 1988-11-22 US disclosed
US-4655824-A Certain trifluoromethoxy-phenoxy-pyridines having herbicidal activity CELAMERCK GMBH & CO. KG (DE) 1987-04-07 US disclosed
EP-0086375-B1 PYRIDINE DERIVATIVES, THEIR PREPARATION AND USE CELAMERCK GmbH & Co. KG (DE) 1986-04-09 EP disclosed
EP-0086375-A2 Pyridine derivatives, their preparation and use CELAMERCK GmbH & Co. KG (DE) 1983-08-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12391663-B2 Isoindolinone compounds CYP4F2, AOC2, AOC3 TSHR 1114/4885ALDH1A1 1142/4885HTT 4306/4885
US-20240083869-A1 ISOINDOLINONE COMPOUNDS CYP4F2, AOC2, AOC3 TSHR 1114/4885ALDH1A1 1142/4885HTT 4306/4885
US-20240216355-A1 PHARMACEUTICAL COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF A DISEASE OR DISORDER CAUSED BY OR ASSOCIATED WITH ONE OR MORE PREMATURE TERMINATION CODONS UPF1, NSUN2, RTF2 TSHR 1410/4885ALDH1A1 4150/4885HTT 868/4885
US-11926632-B2 Methods and compounds for restoring mutant p53 function TP53, TP53BP1, HRAS TSHR 3762/4885ALDH1A1 2214/4885HTT 2757/4885
US-20240051937-A1 ISOINDOLINONE AMIDE COMPOUNDS USEFUL TO TREAT DISEASES ASSOCIATED WITH GSPT1 GSPT2, GSPT1, NMT2 TSHR 1013/4885ALDH1A1 2870/4885HTT 3206/4885
US-20080269277-A1 Pyrrolopyridine-2-Carboxylic Acid Hydrazides PYGL, PDK1, PYGM TSHR 3436/4885ALDH1A1 339/4885HTT 1955/4885
US-11912682-B2 Isoindolinone compounds CYP4F2, AOC2, AOC3 TSHR 1114/4885ALDH1A1 1142/4885HTT 4306/4885
US-20240261274-A1 TREATMENT OF MYC-DRIVEN CANCERS WITH GSPT1 DEGRADERS MYC, MYCBP, GSPT1 TSHR 2333/4885ALDH1A1 4276/4885HTT 835/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.